Yueyao Du

793 total citations
36 papers, 557 citations indexed

About

Yueyao Du is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Yueyao Du has authored 36 papers receiving a total of 557 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cancer Research, 17 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Yueyao Du's work include Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer-related molecular mechanisms research (9 papers). Yueyao Du is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer-related molecular mechanisms research (9 papers). Yueyao Du collaborates with scholars based in China and United States. Yueyao Du's co-authors include Jinsong Lu, Wenjin Yin, Liheng Zhou, Tingting Yan, Yiwei Jiang, Qiong Zhou, Yaohui Wang, Shuguang Xu, Yanping Lin and Huijuan Dai and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Cancer Research.

In The Last Decade

Yueyao Du

33 papers receiving 548 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yueyao Du China	17	255	247	240	115	71	36	557
Sjors G. J. G. In ‘t Veld Netherlands	12	184 0.7×	260 1.1×	275 1.1×	97 0.8×	24 0.3×	28	550
Rafael Caparica Belgium	16	329 1.3×	167 0.7×	163 0.7×	255 2.2×	35 0.5×	35	579
Jinchun Yan United States	13	211 0.8×	324 1.3×	466 1.9×	165 1.4×	29 0.4×	26	807
Kristy Miskimen United States	13	262 1.0×	208 0.8×	392 1.6×	114 1.0×	31 0.4×	31	634
Valentina Caprara Italy	14	118 0.5×	132 0.5×	349 1.5×	43 0.4×	35 0.5×	22	523
Nikolaos Xenidis Greece	16	554 2.2×	372 1.5×	297 1.2×	233 2.0×	32 0.5×	46	936
Julie Godet France	16	196 0.8×	163 0.7×	253 1.1×	161 1.4×	25 0.4×	26	563
Charlotte Abson United Kingdom	8	157 0.6×	71 0.3×	139 0.6×	141 1.2×	84 1.2×	11	500
Jiangang Liu China	11	261 1.0×	186 0.8×	321 1.3×	212 1.8×	17 0.2×	29	628
Ta‐Chun Yuan United States	10	141 0.6×	114 0.5×	378 1.6×	324 2.8×	66 0.9×	11	636

Countries citing papers authored by Yueyao Du

Since Specialization

Citations

This map shows the geographic impact of Yueyao Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yueyao Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yueyao Du more than expected).

Fields of papers citing papers by Yueyao Du

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yueyao Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yueyao Du. The network helps show where Yueyao Du may publish in the future.

Co-authorship network of co-authors of Yueyao Du

This figure shows the co-authorship network connecting the top 25 collaborators of Yueyao Du. A scholar is included among the top collaborators of Yueyao Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yueyao Du. Yueyao Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Du, Yueyao, Liwei Xu, Youhua Jiang, et al.. (2025). Outcomes of neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. Surgery. 183. 109383–109383.

Zeng, Jin, Dong Wang, Zixin Li, et al.. (2025). Development of a prognostic model for osteosarcoma based on macrophage polarization-related genes using machine learning: implications for personalized therapy. Clinical and Experimental Medicine. 25(1). 146–146. 3 indexed citations

Bian, Jin‐Song, Weiwei Chen, Junfeng Shi, et al.. (2025). Androgen receptor–induced lncRNA SOX2-OT promotes triple-negative breast cancer tumorigenesis via targeting miR-320a-5p–CCR5 axis. Journal of Biological Chemistry. 301(4). 108428–108428. 1 indexed citations

Wang, Lulu, Gang Zheng, Yuqin Yang, et al.. (2024). Rolling-Translated circRUNX2.2 Promotes Lymphoma Cell Proliferation and Cycle Transition in Marek’s Disease Model. International Journal of Molecular Sciences. 25(21). 11486–11486.

Yao, Linli, Xiaonan Sheng, Weihang Zhou, et al.. (2023). Neutrophil extracellular traps mediate TLR9/Merlin axis to resist ferroptosis and promote triple negative breast cancer progression. APOPTOSIS. 28(9-10). 1484–1495. 27 indexed citations

Yin, Wenjin, Yaohui Wang, Ziping Wu, et al.. (2022). Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study. Clinical Cancer Research. 28(17). 3677–3685. 26 indexed citations

Dai, Huijuan, et al.. (2022). Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer. Journal of Immunology Research. 2022. 1–14. 4 indexed citations

Zhou, Liheng, Shuguang Xu, Xiaohong Xue, et al.. (2022). Abstract P2-12-02: Efficacy, safety and survival of neoadjuvant chemotherapy with different estrogen deprivation stratified by menstrual status versus chemotherapy alone in locally advanced breast cancer (SHPD002)—— A randomized multicentre, open-label, phase 3 Triab. Cancer Research. 82(4_Supplement). P2–12.

Yan, Tingting, Xinxin Lü, Yueyao Du, et al.. (2022). GLDC mitigated by miR-30e regulates cell proliferation and tumor immune infiltration in TNBC. Frontiers in Immunology. 13. 1033367–1033367. 8 indexed citations

10.

Zhang, Shan, Yaohui Wang, Yan Wang, et al.. (2020). Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy. Frontiers in Oncology. 10. 631–631. 18 indexed citations

11.

Cai, Xin, Yueyao Du, Zheng Wang, et al.. (2020). The role of carbon ion radiotherapy for unresectable locally recurrent rectal cancer: a single institutional experience. Radiation Oncology. 15(1). 209–209. 9 indexed citations

12.

Du, Yueyao, Liheng Zhou, Yanping Lin, et al.. (2019). Polymorphisms in microRNA let-7 binding sites of the HIF1AN and CLDN12 genes can predict pathologic complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer. Annals of Translational Medicine. 7(7). 138–138. 8 indexed citations

13.

Du, Yueyao, Tingting Yan, Liheng Zhou, Wenjin Yin, & Jinsong Lu. (2018). A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer. Breast Cancer Targets and Therapy. Volume 10. 201–206. 4 indexed citations

14.

Wang, Yaohui, Wenjin Yin, Yanping Lin, et al.. (2018). Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer. Cell Death Discovery. 4(1). 21–21. 29 indexed citations

15.

Zhao, Xian, Rong Deng, Yan Wang, et al.. (2017). Twist1/Dnmt3a and miR186 establish a regulatory circuit that controls inflammation-associated prostate cancer progression. Oncogenesis. 6(4). e315–e315. 17 indexed citations

16.

Zhou, Qiong, Wenjin Yin, Yueyao Du, & Jinsong Lu. (2014). For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures. PLoS ONE. 9(1). e83646–e83646. 18 indexed citations

17.

Du, Yueyao, Liheng Zhou, Yaohui Wang, et al.. (2014). Association of alpha2a and beta2 adrenoceptor expression with clinical outcome in breast cancer. Current Medical Research and Opinion. 30(7). 1337–1344. 15 indexed citations

18.

Wang, Yaohui, Yu Liu, Yueyao Du, Wenjin Yin, & Jinsong Lu. (2013). The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis. Current Medical Research and Opinion. 29(6). 633–642. 42 indexed citations

19.

Liu, Yü, Wenjin Yin, Tingting Yan, et al.. (2013). The clinical significance of Ki-67 as a marker of prognostic value and chemosensitivity prediction in hormone-receptor-positive breast cancer: a meta-analysis of the published literature. Current Medical Research and Opinion. 29(11). 1453–1461. 19 indexed citations

20.

Jiang, Yiwei, Wenjin Yin, Liheng Zhou, et al.. (2012). First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis. PLoS ONE. 7(3). e32474–e32474. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact